Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambrx Inks Three-Target Deal With Wyeth To Develop Antibody-Toxin Conjugates

This article was originally published in The Pink Sheet Daily

Executive Summary

First license deal for Ambrx's EuCode technology offers potential for "silver bullet" therapeutics that localize pharmacologic activity.
Advertisement

Related Content

Ambrx Links Its ADC Technology To Japan’s Astellas In Oncology Deal
Merck, Ambrx Partner In Effort To Create Better-Targeted Drug Conjugates
Bristol And Ambrx To Collaborate On Preclinical Assets For Type 2 Diabetes, Heart Failure
Bristol And Ambrx To Collaborate On Preclinical Assets For Type 2 Diabetes, Heart Failure
Ambrx Lands New Merck Serono Deal, This Time In Multiple Sclerosis
Ambrx Lands New Merck Serono Deal, This Time In Multiple Sclerosis

Topics

Advertisement
UsernamePublicRestriction

Register

PS069989

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel